Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma
Stock Information for Sorrento Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.